Results 191 to 200 of about 5,452,327 (324)
Role of hydrogen bonds in molecular relaxation during electron transport processes in biological systems [PDF]
P. M. Krasilnikov
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
A comparative analysis reveals electrogenic properties of PfCRT and pendrin. [PDF]
Gil-Iturbe E, Quick M.
europepmc +1 more source
Positron interactions and transport in biologically relevant molecules [PDF]
C. Makochekanwa +12 more
openalex +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Biopolymer Membranes for Osmotic Power Generation in Bionic Applications. [PDF]
Yu C +6 more
europepmc +1 more source
Generalized Fokker–Planck Theory for Electron and Photon Transport in Biological Tissues: Application to Radiotherapy [PDF]
Edgar Olbrant, Martin Frank
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

